Prion Diseases

"Effective prevention and treatment of prion diseases is focused on two major areas: Preexposure prevention, and post-exposure prophylaxis. To date, attempts to prevent prion disease through vaccination of normal individuals has been limited, whereas progress has been made in distinct therapeutic approaches to limit prion fibril replication following infection. There is no measurable immune response against prions during normal disease progression however, a number of studies have focused on the development of appropriate immunization strategies to develop immunity to PrPC, PrPSc, or both Attempts to develop vaccination strategies in murine models have been hindered by (i) selftolerance to the primary structure of the PrP molecule (ii) potential autoimmune responses to self- PrPC induced by vaccination and (iii) inability to provide protection to cerebral tissues due to immunological preference of the brain, and impermeability of the blood-brain barrier. Similar difficulties have been illustrated in studies designed to uncover effective vaccination strategies for Alzheimer’s disease. Nonetheless, studies have demonstrated the effectiveness of anti-PrP antibodies in blocking both infection and disease progression in vitro(Recent Advances in the Immunity Research of Rabbits to Prion Diseases : Jiapu Zhang) The impact factor is used to compare different journals within a certain field. OMICS Group international, the journal's impact factor is a measure of the frequency with which the average article published in a given scholarly journal has been cited in a particular year or period and is often used to measure or describe the importance of a particular journal to its field. The aggregate impact factor for a subject category is calculated using the same method as the impact factor for a journal, but it also includes the number of citations for all journals in the category and the number of articles from all journals in the category

• Share this page
• 
• 
• 
• 
• 
• 

Last date updated on September, 2024